Quick Answer
BridgeBio Oncology Therapeutics, Inc. reported Net Income of -$134.04 million for fiscal year 2025.
BridgeBio Oncology Therapeutics, Inc. Net Income — Annual History
| Fiscal Year | Net Income | YoY Change |
|---|---|---|
| 2025 | -$134.04M | -80.5% |
| 2024 | -$74.28M | -178051.7% |
| 2023 | -$41.7K | — |
Quarterly Net Income
| Quarter Ending | Net Income | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$44.76M | -158.4% | -57.4% |
| June 30, 2025 | -$28.43M | -30.3% | -28.9% |
| March 31, 2025 | -$22.05M | -42.8% | -27.3% |
| September 30, 2024 | -$17.32M | — | +20.6% |
| June 30, 2024 | -$21.82M | — | -41.3% |
| March 31, 2024 | -$15.44M | — | — |
- BridgeBio Oncology Therapeutics, Inc. showed a decrease of -80.5% in Net Income compared to the prior fiscal year.
- Over the 2023–2025 period, BridgeBio Oncology Therapeutics, Inc.’s net income has declined by 321410.1% (from -$41.7 thousand to -$134.04 million).
- The most recent figure is from BridgeBio Oncology Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 5, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: